VCAM1 and metabolic dysfunction-associated steatohepatitis: Pharmacological inhibition or genetic deletion of VCAM-1 in liver endothelial cells has been shown to reduce liver inflammation, injury, and fibrosis in NASH mice (Furuta et al., 2021) 2021).